Revolution Medicines, Inc. (NASDAQ:RVMD) Accelerates Daraxonrasib Pivotal Push, Data Likely In 2026
Revolution Medicines advances quickly from late-stage enrollment to adjuvant Phase 3 expansion, positioning daraxonrasib for near-term pivotal readouts. Operational momentum and a large liquidity buffer support continued trial execution while technical indicators signal elevated short-term risk of a pullback.







